Shares of Legend Biotech have moved -2.1% today, and are now trading at a price of $45.57. In contrast, the S&P 500 index saw a -0.0% change. Today's trading volume is 965,307 compared to the stock's average volume of 1,212,834.
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Based in Somerset, United States the company has 2,000 full time employees and a market cap of $8,306,636,800.
The company is now trading -45.08% away from its average analyst target price of $82.98 per share. The 19 analysts following the stock have set target prices ranging from $60.0 to $95.0, and on average give Legend Biotech a rating of buy.
Over the last 12 months LEGN shares have declined by -33.3%, which represents a difference of -56.5% when compared to the S&P 500. The stock's 52 week high is $77.32 per share and its 52 week low is $38.6. Based on Legend Biotech's average net margin growth of 15.0% over the last 6 years, its core business remains strong and the stock price may recover in the long term.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2024 | 93,991 | -59,793 | -64 | 64.84 |
| 2023 | 285,143 | -518,254 | -182 | 52.23 |
| 2022 | 117,005 | -446,349 | -381 | 34.98 |
| 2021 | 68,826 | -403,582 | -586 | -65.07 |
| 2020 | 75,000 | -266,373 | -355 | -110.06 |
| 2019 | 59,980 | -101,590 | -169 |
